University of Calgary

Arnie Charbonneau Cancer Institute

Calgary, Alberta

Not yet accepting

EMBRACE

A Study of Elranatamab Management With Outpatient and Intermittent Dosing in Relapsed/Refractory Multiple Myeloma
Learn more
  • Bispecific Antibody
  • BCMA
  • Phase 2

Not currently accepting

Cevostamab

Dose-Escalation Study of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma
Learn more
  • Bispecific Antibody
  • FCRH5
  • Phase 1
  • Has results